3-(chloromethyl)-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one | 99614-72-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(chloromethyl)-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one
• 英文别名: 3-(chloromethyl)-9-methyl-2,3-dihydro-1H-carbazol-4-one
• CAS: 99614-72-9
• 化学式: C₁₄H₁₄ClNO
• 分子量: 247.724
• InChiKey: ZOHGNMNHFUUYCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(chloromethyl)-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one 生成 2,3,4,9-Tetrahydro-N,N,N,9-tetramethyl-4-oxo-1H-carbazole-3-methanaminium iodide
  参考文献：
  名称：

  COATES, I. H.;BELL, J. A.;HUMBER, D. C.;EWAN, G. B.

  摘要：

  DOI：

文献信息

• 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition
  申请人：Glaxo Group Limited

  公开号：US04695578A1

  公开（公告）日：1987-09-22

  The invention relates to compounds of formula (I). ##STR1## wherein R.sub.1 represents a hydrogen atom or a C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, C.sub.3-7 cycloalkyl-(C.sub.1-4) alkyl, C.sub.3-10 alkynyl, phenyl or phenyl-C.sub.1-3 alkyl group, and one of the groups represented by R.sup.2, R.sup.3 and R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl or phenyl-(C.sub.1-3) alkyl group and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group; and physiologically acceptable salts and solvates, e.g. hydrates thereof. The compounds are potent selective antagonists at "neuronal" 5-hydroxytryptamine receptors and are useful in the treatment of migraine and psychotic disorders such as schizophrenia.

  该发明涉及式(I)的化合物。其中R₁代表氢原子或C₁-₁₀烷基，C₃-₇环烷基，C₃-₆烯基，C₃-₇环烷基-(C₁-₄)烷基，C₃-₁₀炔基，苯基或苯基-C₁-₃烷基基团，而由R²、R³和R⁴代表的基团中的一个是氢原子或C₁-₆烷基，C₃-₇环烷基，C₂-₆烯基或苯基-(C₁-₃)烷基基团，另外两个基团，可以相同也可以不同，代表氢原子或C₁-₆烷基基团；以及生理上可接受的盐和溶剂化合物，例如其水合物。这些化合物是“神经元”5-羟色胺受体的有效选择性拮抗剂，并可用于治疗偏头痛和精神分裂症等精神障碍。
• [EN] PROCESS FOR PREPARING 1,2,3,9-TETRAHYDRO-9-METHYL-3-[(2-METHYL-1H-IMIDAZOL-1-YL)METHYL]-4H-CARBAZOL-4-ONE<br/>[FR] METHODE DE PREPARATION DE 1,2,3,9-TETRAHYDRO-9-METHYL-3-[(2-METHYL-1H-IMIDAZOL-1-YL)METHYL]-4H-CARBAZOL-4-ONE
  申请人：BIOGAL GYOGYSZERGYAR

  公开号：WO2003093281A1

  公开（公告）日：2003-11-13

  A process for preparing ondansetron by transamination of an ondansetron structural analog that can be readily prepared conveniently by a Mannich reaction is provided. The process represents an improvement upon known procedures for making ondansetron by transamination because of its rapid rate, selectivity and the ease with which the product can be isolated from the reaction mixture.

  提供一种通过转氨基化反应制备奥昔替尼的方法，该方法可通过Mannich反应方便地制备奥昔替尼结构类似物。该方法改进了已知的通过转氨基化反应制备奥昔替尼的程序，因为其反应速率快、选择性高，并且易于从反应混合物中分离出产物。
• [EN] NEW POLYMORPHIC FORMS OF ONDANSETRON, PROCESSES FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTIEMETICS<br/>[FR] NOUVELLES FORMES POLYMORPHES D'ONDANSETRON ET LEURS PROCEDES DE PREPARATION, ET COMPOSITIONS PHARMACEUTIQUES CONTENANT LESDITES NOUVELLES FORMES POLYMORPHES ET LEUR UTILISATION COMME ANTIVOMITIF
  申请人：VITA CIENTIFICA S L

  公开号：WO2005080381A1

  公开（公告）日：2005-09-01

  This invention relates to new polymorphs of (±)1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-il)methyl]-4H-carbazol-4-one, known under the INN of ondansetron, to processes for preparing said polymorphs, to pharmaceutical compositions containing them and to their use in the treatment and prophylaxis of nausea and vomiting. The invention provides new stable polymorphic forms of ondansetron and processes for manufacturing them at an industrial scale.

  这项发明涉及(±)1,2,3,9-四氢-9-甲基-3-[(2-甲基-1H-咪唑-1-基)甲基]-4H-咔唑-4-酮的新多型体，该化合物以昂丹司琼的国际非专有名称(INN)而闻名，涉及制备该多型体的方法，含有它们的制药组合物以及它们在治疗和预防恶心和呕吐方面的用途。该发明提供了昂丹司琼的新稳定多型体以及在工业规模上制造它们的方法。
• Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
  申请人：Aronhime Judith

  公开号：US20050131045A1

  公开（公告）日：2005-06-16

  Ondansetron crystalline Forms A, B, and B1 are useful in the treatment of nausea and vomiting. Some of the novel forms have uniquely high melting points. The novel forms are stable against thermally induced polymorphic transition from 30° C. up to their melting points.

  Ondansetron晶体形式A、B和B1在治疗恶心和呕吐方面非常有用。其中一些新形式具有独特的高熔点。这些新形式在30°C以上的温度范围内稳定，不会发生热诱导的多形转变，直到它们的熔点。
• Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one
  申请人：Molnar Sandor

  公开号：US20050020655A1

  公开（公告）日：2005-01-27

  A process for preparing ondansetron by transamination of an ondansetron structural analog that can be readily prepared conveniently by a Mannich reaction is provided. The process represents an improvement upon known procedures for making ondansetron by transamination because of its rapid rate, selectivity and the ease with which the product can be isolated from the reaction mixture.

  提供了一种通过转氨基化反应制备昂丹司琼的方法，该方法可以方便地通过曼尼希反应制备昂丹司琼结构类似物。该方法相对于已知的转氨基化反应制备昂丹司琼的方法具有更快的反应速率、更好的选择性以及更容易从反应混合物中分离产物的优点。